Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism.

Slominsky PA, Shadrina MI, Kolomin TA, Stavrovskaya AV, Filatova EV, Andreeva LA, Illarioshkin SN, Myasoedov NF

Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections1 May 2017Cited by 2 (Europe PMC)

PMID28702721DOI10.1134/s0012496617030048PepBankPUB-28702721

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with 6-OHDA induced parkinsonism, Selank did not affect motor activity in the elevated cross shaped maze.
In plain wordsIn rats with induced parkinsonism, Selank did not change movement activity.
Peptide
Selank
Outcome
No significant changeMotor activity
Study
ratn: not reported in source
6-OHDA induced parkinsonism; elevated cross shaped maze
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
It was showed that both peptides did not affect motor activity of rats in elevated cross shaped maze and passive defensive behavior of the animals.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effects of the synthetic regulatory peptides Semax (analog of an ACTH 4-10 fragment (ACTH4-10)) and Selank (analog of immunomodulatory taftsin) on behavior of rats with 6-hydroxidopamine (6-OHDA) induced PD-like parkinsonism.
Report a problemFND-2870272101
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with 6-OHDA induced parkinsonism, Selank did not affect passive defensive behavior.
In plain wordsIn rats with induced parkinsonism, Selank did not change passive defensive behavior.
Peptide
Selank
Outcome
No significant changePassive defensive behavior
Study
ratn: not reported in source
6-OHDA induced parkinsonism; elevated cross shaped maze
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
It was showed that both peptides did not affect motor activity of rats in elevated cross shaped maze and passive defensive behavior of the animals.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effects of the synthetic regulatory peptides Semax (analog of an ACTH 4-10 fragment (ACTH4-10)) and Selank (analog of immunomodulatory taftsin) on behavior of rats with 6-hydroxidopamine (6-OHDA) induced PD-like parkinsonism.
Report a problemFND-2870272102
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with 6-OHDA induced parkinsonism, Semax did not affect motor activity in the elevated cross shaped maze.
In plain wordsIn rats with induced parkinsonism, Semax did not change movement activity.
Peptide
Semax
Outcome
No significant changeMotor activity
Study
ratn: not reported in source
6-OHDA induced parkinsonism; elevated cross shaped maze
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
It was showed that both peptides did not affect motor activity of rats in elevated cross shaped maze and passive defensive behavior of the animals.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effects of the synthetic regulatory peptides Semax (analog of an ACTH 4-10 fragment (ACTH4-10)) and Selank (analog of immunomodulatory taftsin) on behavior of rats with 6-hydroxidopamine (6-OHDA) induced PD-like parkinsonism.
Report a problemFND-2870272103
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with 6-OHDA induced parkinsonism, Semax did not affect passive defensive behavior.
In plain wordsIn rats with induced parkinsonism, Semax did not change passive defensive behavior.
Peptide
Semax
Outcome
No significant changePassive defensive behavior
Study
ratn: not reported in source
6-OHDA induced parkinsonism; elevated cross shaped maze
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
It was showed that both peptides did not affect motor activity of rats in elevated cross shaped maze and passive defensive behavior of the animals.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effects of the synthetic regulatory peptides Semax (analog of an ACTH 4-10 fragment (ACTH4-10)) and Selank (analog of immunomodulatory taftsin) on behavior of rats with 6-hydroxidopamine (6-OHDA) induced PD-like parkinsonism.
Report a problemFND-2870272104
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with toxic damage of dopaminergic neurons, Selank decreased the level of anxiety in the elevated cross shaped maze.
In plain wordsIn rats with damaged dopamine neurons, Selank lowered anxiety.
Peptide
Selank
Outcome
DecreaseAnxiety level in elevated cross shaped maze
Study
ratn: not reported in source
6-OHDA induced parkinsonism; elevated cross shaped maze
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
At the same time, Selank decreased level of anxiety of rats with toxic damage of DA neurons in elevated cross shaped maze.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effects of the synthetic regulatory peptides Semax (analog of an ACTH 4-10 fragment (ACTH4-10)) and Selank (analog of immunomodulatory taftsin) on behavior of rats with 6-hydroxidopamine (6-OHDA) induced PD-like parkinsonism.
Report a problemFND-2870272105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 2
9 Oct 2026, 03:04 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.